Abstract
Get full access to this article
View all access options for this article.
References
1.
Biogen receives a share of U.S. pre-tax profits on sales of Rituxan, which is marketed by Genentech (Roche). Sales figures do not include U.S. revenues generated by Biogen, since the company only discloses those revenues combined with revenues from Gazyva® (obinutuzumab), and does not break out each product separately. Biogen reported combined Rituxan-Gazyva revenues of $1.603 billion for 2019, and $1.502 billion for 2018.
2.
Pfizer markets Enbrel outside the U.S. and Canada, where the treatment is marketed by Amgen. In reporting fourth-quarter and full year results for 2019, Pfizer said the decline in Enbrel sales reflected an 18% decrease operationally in international sales, “primarily reflecting continued biosimilar competition in most developed Europe markets.”
3.
Revlimid was marketed by Celgene until Celgene was acquired by Bristol-Myers Squibb (BMS), in a deal completed November 20, 2019.
4.
Net sales for 2019 is a pro forma figure disclosed by Bristol-Myers Squibb on February 6 during its quarterly conference call with analysts to discuss fourth-quarter and full-year 2019 results. (See Slide 6 of presentation). The 2019 figure for Revlimid includes $8.079 billion in net product sales disclosed by Celgene for the first three quarters of 2019, and $1.299 billion in product revenue figure for the fourth quarter furnished by BMS, which consists solely of product revenues from November 20, 2019 through December 31, 2019. Sales for the specific period from October 1, 2019 through November 19, 2019 have not been published. The 2018 sales figure was disclosed by Celgene.
5.
On December 6, 2019, Merck entity MSD K.K. and Taiho Pharmaceutical, a subsidiary of Otsuka Holdings, announced that they agreed to terminate their co-promotion agreement for Keytruda at the end of December 2019. MSD agreed to continue manufacturing, distribution and promotion of Keytruda.
6.
Pfizer figures for Eliquis consist of “alliance revenues” reflecting products co-developed with partner companies, as well as direct sales in some regions of the world.